151 related articles for article (PubMed ID: 38767710)
1. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement.
Cheng J; Peng Y; Wu Q; Wu Q; He J; Yuan G
Clin Rheumatol; 2024 Jul; 43(7):2229-2236. PubMed ID: 38767710
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
Fan Q; Yang H; Liu Y
Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study.
Huang X; Lin F; Chen H
Clin Exp Nephrol; 2024 Apr; ():. PubMed ID: 38613741
[TBL] [Abstract][Full Text] [Related]
4. [Hematological abnormalities in systemic lupus erythematosus and clinical significance thereof: comparative analysis of 236 cases].
Chen JL; Huang XM; Zeng XJ; Wang Y; Zhou MX; Ma YH; Li RS; Shen T
Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1330-3. PubMed ID: 17727778
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study.
Chen R; Fu R; Lin Z; Huang C; Huang W
Lupus; 2023 Jan; 32(1):94-100. PubMed ID: 36416639
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study.
Jin HZ; Li YJ; Wang X; Li Z; Ma B; Niu L; Wang P; Pan HF; Li SD; Bao W; Wang G; Li XM; Chen Z
Lupus Sci Med; 2023 Nov; 10(2):. PubMed ID: 38007228
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial.
Sun L; Shen Q; Gong Y; Li Y; Lv Q; Liu H; Zhao F; Yu H; Qiu L; Li X; He X; Chen Y; Xu Z; Xu H
Lupus; 2022 Jul; 31(8):998-1006. PubMed ID: 35499216
[TBL] [Abstract][Full Text] [Related]
8. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
Ho A; Barr SG; Magder LS; Petri M
Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
[TBL] [Abstract][Full Text] [Related]
9. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
10. Association of Serum Ferritin Levels with Hematological Manifestations in Systemic Lupus Erythematosus Patients from Western India.
Pradhan V; Pandit P; Rajadhyaksha A; Patwardhan M; Surve P; Kamble P; Lecerf M; Bayry J; Kaveri S; Ghosh K; Nadkar MY
J Assoc Physicians India; 2016 May; 64(5):14-18. PubMed ID: 27735143
[TBL] [Abstract][Full Text] [Related]
11. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
[TBL] [Abstract][Full Text] [Related]
12. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.
Julkunen H; Ekblom-Kullberg S; Miettinen A
Rheumatol Int; 2012 Aug; 32(8):2445-51. PubMed ID: 21706294
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
14. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
Miyawaki S; Nishiyama S; Aita T; Yoshinaga Y
Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
[TBL] [Abstract][Full Text] [Related]
15. Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus.
Sun J; Li X; Zhou H; Liu X; Jia J; Xie Q; Peng S; Sun X; Wang Q; Yi L
J Immunol Res; 2019; 2019():7430780. PubMed ID: 31049359
[TBL] [Abstract][Full Text] [Related]
16. Elevated Serum Interleukin-34 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity.
Xie HH; Shen H; Zhang L; Cui MY; Xia LP; Lu J
Sci Rep; 2018 Feb; 8(1):3462. PubMed ID: 29472590
[TBL] [Abstract][Full Text] [Related]
17. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
Ma X; Fu X; Cui B; Lin H
Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
[TBL] [Abstract][Full Text] [Related]
18. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus.
Sun L; Wang D; Liang J; Zhang H; Feng X; Wang H; Hua B; Liu B; Ye S; Hu X; Xu W; Zeng X; Hou Y; Gilkeson GS; Silver RM; Lu L; Shi S
Arthritis Rheum; 2010 Aug; 62(8):2467-75. PubMed ID: 20506343
[TBL] [Abstract][Full Text] [Related]
19. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
Nasiri S; Karimifar M; Bonakdar ZS; Salesi M
Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
